Drug Lobby Challenges Washington State 340B Pharmacy Law

Key Takeaways

• A pharmaceutical industry trade group filed a federal lawsuit challenging Washington’s new 340B law, which regulates manufacturer relationships with contract pharmacies and expands state oversight.
• The complaint alleges the law is preempted by federal 340B requirements and violates constitutional limits by imposing additional obligations on drug manufacturers.
• The case could influence how far states can go in regulating the 340B program and may impact pharmacy access, compliance requirements, and manufacturer distribution policies nationwide.

A pharmaceutical industry lobbying group has filed suit challenging a new Washington state law regulating aspects of the federal 340B drug pricing program, setting up another high-stakes legal dispute over the balance of state authority and federal oversight in pharmaceutical pricing and distribution.

Background on the Washington Law

The challenged statute, Senate Bill 5981, is designed to increase oversight and transparency within the 340B program and to limit drug manufacturers’ ability to restrict how covered entities dispense discounted medications.

The 340B program, established in 1992, requires pharmaceutical manufacturers to provide discounted outpatient drugs to qualifying safety-net providers, such as hospitals and clinics serving low-income or rural populations.

Washington’s law specifically seeks to do the following:

• Prevent manufacturers from limiting the use of contract pharmacies to dispense 340B drugs
• Restrict manufacturers from requiring certain claims or pricing data as a condition of participation
• Expand enforcement authority for the state and covered entities

The law is scheduled to take effect in 2026 and reflects a broader trend of states enacting protections for contract pharmacy arrangements under the 340B program.

The Lawsuit

The lawsuit, filed by Pharmaceutical Research and Manufacturers of America (PhRMA), challenges the Washington statute on multiple legal grounds. At the center of the dispute is whether the state law improperly interferes with the federally governed 340B program.

Drug manufacturers argue the following:

• The law conflicts with federal 340B requirements and exceeds state authority
• It imposes obligations not required under federal law, including expanded discounting and operational mandates
• It may violate constitutional principles, including limits on state regulation of interstate commerce

For example, one manufacturer contends the law would force it to provide additional discounts and incur compliance costs beyond federal requirements, resulting in significant financial losses.

Additionally, industry plaintiffs argue that Washington’s restrictions on data collection and pharmacy network limitations undermine safeguards intended to prevent duplicate discounts and drug diversion within the 340B system.

State Position and Policy Context

Washington officials have indicated confidence in the law’s legality and have emphasized its role in protecting access to discounted medications and strengthening oversight of the 340B program.

Supporters of the law, including health care providers, argue that contract pharmacies are essential for expanding patient access, particularly for entities that lack in-house dispensing capabilities.

The dispute reflects longstanding tension between manufacturers and covered entities over the scope of the 340B program, especially regarding the use of contract pharmacies and the distribution of program savings.

Broader Implications

The outcome of the litigation could have national implications. Multiple states have enacted or proposed similar laws, and courts have issued mixed rulings in related disputes involving manufacturer restrictions and federal enforcement authority.

A ruling in favor of the pharmaceutical industry could reinforce arguments that manufacturer policies governing contract pharmacies are permissible under federal law. Conversely, a decision upholding Washington’s statute may strengthen states’ ability to regulate aspects of the 340B program and protect pharmacy access.

What’s Next

The plaintiffs are seeking to block enforcement of the law while the case proceeds. As of now, the state has not formally responded in court, and no hearing date has been publicly set.

Pharmacists and stakeholders in the 340B ecosystem should monitor this case closely, as it may shape future compliance requirements, contract pharmacy operations, and the evolving interplay between state and federal regulation of drug pricing programs.

Reference

1. Pharmaceutical Research and Manufacturers of America v Brown NW, Moran R. No. 3:26-cv-05374 (WD Wash. 2026). Accessed April 27, 2026. https://aboutblaw.com/blqz
2. Belloni G. Drug lobby files suit challenging Washington pharmacy law. Bloomberg Law. Published April 13, 2026. Accessed April 27, 2026. https://news.bloomberglaw.com/health-law-and-business/drug-lobby-files-suit-challenging-washington-pharmacy-law